Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Lectin-like oxidized low-density lipoprotein receptor 1 attenuates pneumonia-induced lung injury
Filiz T. Korkmaz, Anukul T. Shenoy, Elise M. Symer, Lillia A. Baird, Christine V. Odom, Emad I. Arafa, Ernest L. Dimbo, Elim Na, William Molina-Arocho, Matthew Brudner, Theodore J. Standiford, Jawahar L. Mehta, Tatsuya Sawamura, Matthew R. Jones, Joseph P. Mizgerd, Katrina E. Traber, Lee J. Quinton
Filiz T. Korkmaz, Anukul T. Shenoy, Elise M. Symer, Lillia A. Baird, Christine V. Odom, Emad I. Arafa, Ernest L. Dimbo, Elim Na, William Molina-Arocho, Matthew Brudner, Theodore J. Standiford, Jawahar L. Mehta, Tatsuya Sawamura, Matthew R. Jones, Joseph P. Mizgerd, Katrina E. Traber, Lee J. Quinton
View: Text | PDF
Research Article Immunology Inflammation

Lectin-like oxidized low-density lipoprotein receptor 1 attenuates pneumonia-induced lung injury

  • Text
  • PDF
Abstract

Identifying host factors that contribute to pneumonia incidence and severity are of utmost importance to guiding the development of more effective therapies. Lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1, encoded by OLR1) is a scavenger receptor known to promote vascular injury and inflammation, but whether and how LOX-1 functions in the lung are unknown. Here, we provide evidence of substantial accumulation of LOX-1 in the lungs of patients with acute respiratory distress syndrome and in mice with pneumonia. Unlike previously described injurious contributions of LOX-1, we found that LOX-1 is uniquely protective in the pulmonary airspaces, limiting proteinaceous edema and inflammation. We also identified alveolar macrophages and recruited neutrophils as 2 prominent sites of LOX-1 expression in the lungs, whereby macrophages are capable of further induction during pneumonia and neutrophils exhibit a rapid, but heterogenous, elevation of LOX-1 in the infected lung. Blockade of LOX-1 led to dysregulated immune signaling in alveolar macrophages, marked by alterations in activation markers and a concomitant elevation of inflammatory gene networks. However, bone marrow chimeras also suggested a prominent role for neutrophils in LOX-1–mediated lung protection, further supported by LOX-1+ neutrophils exhibiting transcriptional changes consistent with reparative processes. Taken together, this work establishes LOX-1 as a tissue-protective factor in the lungs during pneumonia, possibly mediated by its influence on immune signaling in alveolar macrophages and LOX-1+ airspace neutrophils.

Authors

Filiz T. Korkmaz, Anukul T. Shenoy, Elise M. Symer, Lillia A. Baird, Christine V. Odom, Emad I. Arafa, Ernest L. Dimbo, Elim Na, William Molina-Arocho, Matthew Brudner, Theodore J. Standiford, Jawahar L. Mehta, Tatsuya Sawamura, Matthew R. Jones, Joseph P. Mizgerd, Katrina E. Traber, Lee J. Quinton

×

Figure 6

Alveolar macrophages exhibit a dysregulated phenotype with LOX-1 inhibition.

Options: View larger image (or click on image) Download as PowerPoint
Alveolar macrophages exhibit a dysregulated phenotype with LOX-1 inhibit...
(A) Age-matched C57BL/6 mice were intratracheally treated with 10 μg anti–LOX-1 IgG or control IgG and E. coli for 6–36 hours (n = 6–8 per group). FACS-sorted alveolar macrophages were subsequently analyzed by flow cytometry for (B) levels of reactive oxygen species (ROS) at 6 hours, (C) IL-6 and CXCL2 expression at 24 hours, or (D) CD206 expression at 18 hours after anti–LOX-1 or IgG treatment and infection. Intracellular flow cytometry was performed on fixed cells at 18–36 hours after anti–LOX-1 or control IgG treatment and E. coli infection to determine (E) Arginase 1, iNOS, MHCII, and CD11b expression (MFI) and (F) total alveolar macrophage numbers. Data are represented as mean ± SEM with individual data points representative of mice from 2–3 independent experiments. Statistical analysis was performed on normalized (log-transformed) IL-6 and CXCL2 gene expression (fold change). ***P < 0.001, *P < 0.05 for 1-way ANOVA with Holm-Šídák post hoc test (B); 2-tailed Welch’s t test (C); 2-tailed, unpaired t test (D); or 2-way ANOVA with Holm-Šídák post hoc test (D and E).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts